Please use this identifier to cite or link to this item:
Title: Personalized Chemosensitivity Assays for Mesothelioma: Are They Worth the Effort?
Austin Authors: John, Thomas ;Chia, Puey Ling 
Affiliation: Faculty of Medicine, University of Melbourne, Melbourne, Victoria, Australia
Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia
Department of Medical Oncology, Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australia
Issue Date: 1-Apr-2018 2018-01-19
Publication information: Clinical Cancer Research 2018; 24(7): 1513-1515
Abstract: Cell lines formed from an individual's tumor can be used to predict response to specific therapies and determine genomic predictors. For mesothelioma, where chemotherapy remains the backbone of current therapeutic paradigms, such assays could be used to treat patients with the most effective agents specific to their "chemical profile." Clin Cancer Res; 24(7); 1513-5. ©2018 AACRSee related article by Schunselaar et al., p. 1761.
DOI: 10.1158/1078-0432.CCR-17-3493
PubMed URL: 29351918
ISSN: 1078-0432
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.